P. Trimoulet, J. Izopet, L. Serfaty, V. Paradis, B. Spire et al., A. Pailhé. Clinical Centres

, APHP Pitié-Salpétrière

, APHP Pitié-Salpétrière

. Aphm-sainte-marguerite, Marseille (Service d'Immuno-Hématologie Clinique

, Paris (Maladies Infectieuses et Tropicales: G. Pialoux

:. P. Anatomo-pathologie, F. Callard, :. C. Bendjaballah;-virologie, and . Le-pendeven,

, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérolo-gie: L. Alric, K. Barange, S. Metivier; Anatomo-pathologie, Virologie: F. Larroquette

, Infectiologie: A. Naqvi, V. Rio; Anatomopathologie, Virologie: C. Partouche)

, Médecine Interne-Unité VIH: O. Bouchaud; Anatomo-pathologie: M. Ziol; Virologie: Y. Baazia)

D. Garipuy and M. J. Ferro-collados,

. Anatomo-pathologie, Virologie: F. Nicot

-. Aphp-bichat, Virologie: G. Alexandre

A. Saint-louis,

. Anatomo-pathologie, P. Bertheau

;. K. Aphp-saint-antoine, J. Lacombe, ;. Bottero, P. M. Krause, and . Girard, Maladies Infectieuses et Tropicales

J. Cervera, :. C. Adam;-virologie, and . Viala,

. Aphp-bicêtre, :. C. Paris-(médecine-interne, Y. Goujard, E. Quertainmont, and . Teicher, Virologie: C. Pallier; Maladies Infectieuses: D. Vittecoq

. Aphp-necker, . Paris-(maladies-infectieuses, :. O. Tropicales, C. Lortholary, C. Duvivier et al., Virologie: V. Avettand-Fenoel, A. Mélard

M. Infectieuses, :. D. Tropicales, A. Neau, E. Ochoa, S. Blanchard et al., Virologie: P. Trimoulet, S. Reigadas

H. Saint-andré, ;. D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar et al., Médecine Interne et Maladies Infectieuses: Médecine Interne et Maladies Infectieuses: P. Morlat

. Hôpital-du-haut-levêque, :. J. Bordeaux-(médecine-interne, J. F. Pellegrin, E. Viallard, C. Lazzaro et al., Virologie: P. Trimoulet, S. Reigadas

F. Hôpital, :. D. Suresnes-(médecine-interne, C. Zucman, and . Majerholc,

. Aphp-antoine-béclère, :. F. Clamart-(médecine-interne, J. Boué, I. Devoto, V. Kansau et al.,

H. Chu and . Mondor,

A. S. Lelièvre, G. Lascaux, and . Melica,

E. Billaud, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille et al., Virologie: A. Rodallec

. Hôpital-de-la-croix-rousse, Lyon (Maladies Infectieuses et Tropicales: P

D. Miailhes, C. Peyramond, F. Chidiac, F. Ader, A. Biron et al.,

T. T. Scholtes and . Le-thi,

D. Simonet-lann and . Croisier-bertin,

P. Ch-perpignan, Maladies infectieuses et tropicales: H. Aumaître)

;. F. Chu-robert-debré, D. Bani-sadr, . Lambert, J. L. Nguyen, and . Berger, Reims (Médecine interne, maladies infectieuses et immunologie clinique

D. Rey, . Partisani, C. Batard, M. Cheneau, . Priester et al.,

F. Bedel, C. Touam, M. Louisin, C. Mole, M. Bolliot et al.,

E. Boerg, P. Carrieri, V. Conte, L. Dequae-merchadou, M. Desvallees et al., Management

. Who-|-hepatitis, , 2018.

S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss et al., Expert opinion on the treatment of patients with chronic hepatitis C, J Viral Hepat, vol.16, p.18761607, 2009.

R. P. Ward and M. Kugelmas, Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C, Am Fam Physician, vol.72, p.16127955, 2005.

S. S. Lee, V. G. Bain, K. Peltekian, M. Krajden, E. M. Yoshida et al., Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice, Aliment Pharmacol Ther, vol.23, p.16422999, 2006.

J. Pawlotsky, Hepatitis C treatment: the data flood goes on-an update from the liver meeting, Gastroenterology, vol.148, p.25576860, 2014.

M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-torres, K. R. Reddy, T. Hassanein et al., Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, vol.370, p.24428467, 2014.

P. Sogni, C. Gilbert, K. Lacombe, L. Piroth, E. Rosenthal et al., All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort, Clin Infect Dis, vol.63, p.27317796, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01993207

L. Piroth, L. Wittkop, K. Lacombe, E. Rosenthal, C. Gilbert et al., Efficacy and safety of directacting antiviral regimens in HIV/HCV-co-infected patients-French ANRS CO13 HEPAVIH cohort, J Hepatol

E. R. Cachay, L. Hill, D. Wyles, B. Colwell, C. Ballard et al., The Hepatitis C Cascade of Care among HIV Infected Patients: A Call to Address Ongoing Barriers to Care, PLoS ONE, vol.9, 2014.

L. Craxì, D. Sacchini, P. Refolo, R. Minacori, V. Daloiso et al., Prioritization of high-cost new drugs for HCV: making sustainability ethical, Eur Rev Med Pharmacol Sci, vol.20, p.27049255, 2016.

A. France-presse, Hépatite C: des traitements très efficaces mais qui profitent à très peu, 2016.

B. T. Clark, G. Garcia-tsao, and L. Fraenkel, Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection, Patient Prefer Adherence, vol.6, p.22536063, 2012.

, Discours de Marisol Touraine-Journée de lutte contre les hépatites virales

M. Solidar and . Santé, , 2016.

D. Dhumeaux, Prise en charge thérapeutique et suivi de l'ensemble des personnes infectées par le virus de l'hépatite C. RAPPORT DE RECOMMANDATIONS, p.108, 2016.

S. Saeed, E. C. Strumpf, S. L. Walmsley, K. Rollet-kurhajec, N. Pick et al., How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.62, pp.919-945, 2016.

M. Zeremski, J. E. Zibbell, A. D. Martinez, S. Kritz, B. D. Smith et al., Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care, World J Gastroenterol WJG, vol.19, p.24307778, 2013.

P. Roux, B. Demoulin, P. Sogni, M. P. Carrieri, R. Dray-spria et al., La co-infection par le virus de l'hépatite C chez les personnes infectées par le VIH: données de l'enquête ANRS-Vespa2, Bull Epidé-miologique Hebd, pp.314-334, 2013.

D. Salmon-ceron, J. Cohen, M. Winnock, P. Roux, F. B. Sadr et al., Engaging HIV-HCV coinfected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France), BMC Health Serv Res, vol.12, p.22409788, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00687514

L. Wiessing, M. Ferri, B. Grady, M. Kantzanou, I. Sperle et al., Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention, PLOS ONE, vol.9, p.25068274, 2014.

L. E. Taylor, T. Swan, and K. H. Mayer, HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.55, issue.1, pp.33-42, 2012.

M. Loko, D. Salmon, P. Carrieri, M. Winnock, M. Mora et al., The French national prospective cohort of patients co-infected with HIV and HCV, ANRS CO13 HEPAVIH): Early findings, vol.10, p.20969743, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

K. A. Bradley, A. F. Debenedetti, R. J. Volk, E. C. Williams, D. Frank et al., AUDIT-C as a brief screen for alcohol misuse in primary care, Alcohol Clin Exp Res, vol.31, p.17451397, 2007.

R. K. Sterling, E. Lissen, N. Clumeck, R. Sola, M. C. Correa et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, vol.43, p.16729309, 2006.

E. Focà, M. Fabbiani, M. Prosperi, Q. Roldan, E. Castelli et al., Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA. Medicine (Baltimore), vol.95, 2016.

P. Vickerman, N. Martin, K. Turner, and M. Hickman, Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings, Addict Abingdon Engl, vol.107, pp.1984-95, 2012.

A. A. Aidala, M. G. Wilson, V. Shubert, D. Gogolishvili, J. Globerman et al., Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review, Am J Public Health, vol.106, pp.1-23, 2016.

C. Kim, T. Kerr, K. Li, R. Zhang, M. W. Tyndall et al., Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting, BMC Public Health, vol.9, p.270, 2009.

N. H. Afdhal, S. Zeuzem, R. T. Schooley, D. L. Thomas, J. W. Ward et al., The new paradigm of hepatitis C therapy: integration of oral therapies into best practices, J Viral Hepat, vol.20, p.24168254, 2013.

S. M. Lynch and G. Y. Wu, Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy, J Clin Transl Hepatol, vol.4, p.28097100, 2016.

M. J. Alter, Epidemiology of hepatitis C virus infection, World J Gastroenterol WJG, vol.13, p.17552026, 2007.

M. Hellard, R. Sacks-davis, and J. Gold, Hepatitis C treatment for injection drug users: a review of the available evidence, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.49, pp.561-73, 2009.

V. Mrav?ík, L. Strada, J. Bencko, V. Groshkova, T. Reimer et al., Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review, Patient Prefer Adherence, vol.7, p.24204126, 2013.

P. Bruggmann and J. Grebely, Prevention, treatment and care of hepatitis C virus infection among people who inject drugs, Int J Drug Policy, vol.26, issue.1, pp.22-26, 2015.

J. Grebely, M. Oser, L. E. Taylor, and G. J. Dore, Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels, J Infect Dis, vol.207, p.23390301, 2013.

N. K. Martin, P. Vickerman, J. Grebely, M. Hellard, S. J. Hutchinson et al., Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of directacting antivirals, Hepatol Baltim Md, vol.58, pp.1598-609, 2013.

L. E. Taylor, T. Swan, and G. V. Matthews, Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.57, pp.118-142, 2013.

S. Saeed, E. C. Strumpf, E. E. Moodie, J. Young, R. Nitulescu et al., Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada, J Int AIDS Soc, vol.20, 2017.

G. Robaeys, H. Van-vlierberghe, C. Matheï, M. Van-ranst, L. Bruckers et al., Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes, Eur J Gastroenterol Hepatol, vol.18, p.16394797, 2006.

D. Sylvestre, Hepatitis C treatment in drug users: perception versus evidence, Eur J Gastroenterol Hepatol, vol.18, p.16394792, 2006.

M. Hopwood and C. Treloar, The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection, Int J Drug Policy, vol.18, p.17854725, 2007.

A. Bouhnik, M. P. Carrieri, D. Rey, B. Spire, J. Gastaut et al., Drug injection cessation among HIV-infected injecting drug users, Addict Behav, vol.29, p.15236822, 2004.

J. L. Scavone, R. C. Sterling, and E. J. Van-bockstaele, Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal, Neuroscience, vol.248, p.23624062, 2013.

P. O'campo, V. Stergiopoulos, P. Nir, M. Levy, V. Misir et al., How did a Housing First intervention improve health and social outcomes among homeless adults with mental illness in Toronto? Two-year outcomes from a randomised trial, BMJ Open, vol.6, 2016.

R. A. Cherner, A. T. Sylvestre, J. Boyd, R. Pettey, and D. , Housing First for Adults with Problematic Substance Use, J Dual Diagn, p.0, 2017.

M. D. Sadler and S. S. Lee, Revolution in hepatitis C antiviral therapy, Br Med Bull, vol.113, p.25680808, 2015.

L. Benítez-gutiérrez, P. Barreiro, P. Labarga, C. De-mendoza, J. V. Fernandez-montero et al., Prevention and management of treatment failure to new oral hepatitis C drugs, Expert Opin Pharmacother, vol.17, p.27149603, 2016.

W. Wong, K. M. Lee, S. Singh, G. Wells, J. J. Feld et al., Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis, CMAJ Open, vol.5, p.28401125, 2017.

L. Craxì, C. Cammà, and A. Craxì, HCV: the best cure possible or the best possible cure?, J Viral Hepat, vol.22, p.26135025, 2015.